We are live on ! Find out more
GALT icon

Galectin Therapeutics
GALT

65 hedge funds and large institutions have $37.3M invested in Galectin Therapeutics in 2019 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 15 increasing their positions, 14 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

87% more capital invested

Capital invested by funds: $20M → $37.3M (+$17.3M)

42% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 12

7% more funds holding

Funds holding: 61 → 65 (+4)

1.95% more ownership

Funds ownership: 14.08% → 16.03% (+1.9%)

7% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 14

25% less call options, than puts

Call options by funds: $2.04M | Put options by funds: $2.71M

Holders
65
Holders Change
+4
Holders Change %
+6.56%
% of All Funds
1.41%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
17
Increased
15
Reduced
14
Closed
12
Calls
$2.04M
Puts
$2.71M
Net Calls
-$672K
Net Calls Change
+$142K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$1.75M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$1.35M
3
CS
Credit Suisse
Switzerland
+$964K
4
JP Morgan Chase
JP Morgan Chase
New York
+$906K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$848K

Top Sellers

Rank Fund Capital Flow
1
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$1M
2
MIM
Monashee Investment Management
Massachusetts
-$223K
3
Barclays
Barclays
United Kingdom
-$203K
4
OAM
Oxford Asset Management
United Kingdom
-$145K
5
Wolverine Trading
Wolverine Trading
Illinois
-$101K
Name Holding Trade Value Shares
Change 		Change in
Stake
BWM
26
BT Wealth Management
Georgia
$256K – – –
PNC Financial Services Group
27
PNC Financial Services Group
Pennsylvania
$241K – – –
BCM
28
BlueCrest Capital Management
Jersey
$231K +$65.6K +13,666 +43%
SWP
29
Stratos Wealth Partners
Ohio
$209K – – –
LPL Financial
30
LPL Financial
California
$163K +$14.4K +3,000 +10%
WG
31
Winton Group
United Kingdom
$150K +$141K +29,293 New
BAM
32
Belpointe Asset Management
Nevada
$138K +$130K +26,998 New
JG
33
Jefferies Group
New York
$137K +$129K +26,800 New
California Public Employees Retirement System
34
California Public Employees Retirement System
California
$120K – – –
Jane Street
35
Jane Street
New York
$113K +$106K +22,029 New
Bank of America
36
Bank of America
North Carolina
$112K +$84.6K +17,629 +401%
MML Investors Services
37
MML Investors Services
Massachusetts
$106K -$29.5K -6,142 -23%
Citadel Advisors
38
Citadel Advisors
Florida
$104K -$1.52K -316 -2%
Bank of New York Mellon
39
Bank of New York Mellon
New York
$99K -$2.77K -578 -3%
AGM
40
Alpine Global Management
New York
$98K -$20.4K -4,258 -18%
CAN
41
Cetera Advisor Networks
California
$96K – – –
WS
42
Wedbush Securities
California
$92K – – –
LWAC
43
Laurel Wealth Advisors (California)
California
$85K – – –
D.E. Shaw & Co
44
D.E. Shaw & Co
New York
$84K +$78.5K +16,350 New
IWM
45
IHT Wealth Management
Illinois
$82K +$26.6K +5,550 +53%
BFM
46
Boothbay Fund Management
New York
$78K -$73.1K -15,229 -50%
Thrivent Financial for Lutherans
47
Thrivent Financial for Lutherans
Minnesota
$78K +$72.9K +15,178 New
Verition Fund Management
48
Verition Fund Management
Connecticut
$76K +$71.1K +14,808 New
JA
49
JOYN Advisors
Georgia
$65K – – –
Commonwealth Equity Services
50
Commonwealth Equity Services
Massachusetts
$62K +$4.8K +1,000 +9%
1
2
3

GALT Hedge Fund Activity: Q1 2019 in Review

65 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q1 2019, worth a combined $37.3M — up 87% from $20M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new GALT positions and 12 closed out — a net gain of 5 holders — while 15 added to existing stakes and 14 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $1.75M. The largest seller was Bank of Montreal, cutting an estimated $1M.

  • 65 institutional investors held Galectin Therapeutics (GALT) as of Q1 2019, up from 61 in Q4 2018.
  • Funds reported $37.3M of Galectin Therapeutics stock for Q1 2019, up 87% quarter-over-quarter.
  • 17 funds opened new Galectin Therapeutics positions in Q1 2019 and 12 closed out, a net change of +5 holders.
  • The largest Galectin Therapeutics buyer in Q1 2019 was Millennium Management, an estimated $1.75M added.
  • The largest Galectin Therapeutics seller in Q1 2019 was Bank of Montreal, an estimated $1M sold.

Based on aggregated 13F filings for Q1 2019.